Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size
3 studies found for:    22067384 [PUBMED-IDS]

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Completed Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia
Conditions: Immunosuppresion;   Thrombocytopenia;   Pancytopenia;   Neutropenia
Interventions: Biological: Anti-thymocyte globulin (rabbit);   Biological: Anti-thymocyte globulin (horse);   Drug: Cyclosporine
2 Active, not recruiting Alemtuzumab to Treat Severe Aplastic Anemia
Conditions: Relapsed or Refractory Severe Aplastic Anemia;   Severe Aplastic Anemia
Intervention: Drug: Alemtuzumab (Campath )
3 Completed
Has Results 		Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
Condition: Aplastic Anemia
Interventions: Drug: Campath-1H;   Drug: r-ATG;   Drug: CsA
To Top

† Indicates status has not been verified in more than two years